SCHEMBL6824349

SCHEMBL6824349

CC(C)C(NC(=O)CCc1ccccc1)P(=O)(O)CC(CCCCN)C(=O)O

nearest known ligand 0.98

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
CPB2 Q96IY4 3/20 0.98
CPA1 P15085 6/20 0.58
CPA2 P48052 6/20 0.58
CPA4 Q9UI42 6/20 0.58
ERAP2 Q6P179 3/20 0.49
ERAP1 Q9NZ08 3/20 0.49
LNPEP Q9UIQ6 1/20 0.49
F2 P00734 3/20 0.46
MMP3 P08254 1/20 0.44
F10 P00742 1/20 0.44
LAP3 P28838 3/20 0.44
PLG P00747 1/20 0.44
PLAT P00750 1/20 0.44
PRSS1 P07477 1/20 0.44
ANPEP P15144 1/20 0.44
ITGB3 P05106 1/20 0.44
ITGA2B P08514 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6827926 1.00 CPB2 (0.98) CPB2CPA1CPA2CPA4ERAP2
SCHEMBL6827930 1.00 CPB2 (0.98) CPB2CPA1CPA2CPA4ERAP2
SCHEMBL6824195 0.99 CPB2 (1.00) CPB2CPA1CPA2CPA4ERAP2
SCHEMBL14542979 0.99 CPB2 (1.00) CPB2CPA1CPA2CPA4ERAP2
SCHEMBL14509143 0.90 CPB2 (0.83) CPB2CPA1CPA2CPA4MMP3
SCHEMBL6827315 0.83 CPB2 (0.70) CPB2MMP3
SCHEMBL6827149 0.81 CPB2 (0.67) CPB2CPA1CPA2CPA4F2
SCHEMBL6827927 0.81 CPB2 (0.67) CPB2CPA1CPA2CPA4F2
SCHEMBL6827300 0.81 CPB2 (0.67) CPB2CPA1CPA2CPA4F2
SCHEMBL6824289 0.81 CPB2 (0.67) CPB2CPA1CPA2CPA4F2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1152004-B1 Phosphonic acid derivatives having carboxypeptidase B inhibitory action MEIJI SEIKA KAISHA (JP) 2003-05-07 EP claimed
EP-1152004-A1 PHOSPHONIC ACID DERIVATIVES HAVING CARBOXYPEPTIDASE B INHIBITORY ACTIVITY MEIJI SEIKA KAISHA LTD. (JP) 2001-11-07 EP claimed
US-6737416-B2 THROMBOLYTIC AGENT HAVING HIGHER SAFETY MEIJI SEIKA KAISHA LTD. (JP) 2004-05-18 US disclosed
US-20030119787-A1 Phosphonic acid derivative having inhibitory activity against carboxypeptidase B MEIJI SEIKA KAISHA LTD. (JP) 2003-06-26 US disclosed
US-6576627-B1 Such as 7-amino-2-((2-methyl-1-(3-phenylpropanoylamino)-propyl)hydroxyphosphinoyl) -methylheptanoic acid; thrombotic disease MEIJI SEIKA KAISHA LTD. (JP) 2003-06-10 US disclosed
EP-1152004-B1 Phosphonic acid derivatives having carboxypeptidase B inhibitory action MEIJI SEIKA KAISHA (JP) 2003-05-07 EP disclosed
EP-1174434-A1 Phosphonic acid derivative having inhibitory activity against carboxypeptidase B MEIJI SEIKA KAISHA LTD. (JP) 2002-01-23 EP disclosed
EP-1152004-A1 PHOSPHONIC ACID DERIVATIVES HAVING CARBOXYPEPTIDASE B INHIBITORY ACTIVITY MEIJI SEIKA KAISHA LTD. (JP) 2001-11-07 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030119787-A1 Phosphonic acid derivative having inhibitory activity against carboxypeptidase B CPB1, RNPEP, CPN1 CPB2 8/4885CPA1 6/4885CPA2 14/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.